See more : S-Tech Corp. (1584.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of SeqLL Inc. (SQLLW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SeqLL Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- cyan AG (CCYNF) Income Statement Analysis – Financial Results
- Ratos AB (publ) (RATO-B.ST) Income Statement Analysis – Financial Results
- Foresight Enterprise VCT Plc (FTF.L) Income Statement Analysis – Financial Results
- Olectra Greentech Limited (OLECTRA.NS) Income Statement Analysis – Financial Results
- Pan-International Industrial Corp. (2328.TW) Income Statement Analysis – Financial Results
SeqLL Inc. (SQLLW)
About SeqLL Inc.
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 78.66K | 210.00K | 329.50K | 533.13K | 779.07K | 1.34M | 939.68K |
| Cost of Revenue | 154.23K | 200.61K | 144.13K | 170.80K | 219.76K | 674.28K | 1.08M | 520.10K |
| Gross Profit | -154.23K | -121.95K | 65.86K | 158.69K | 313.37K | 104.79K | 254.23K | 419.59K |
| Gross Profit Ratio | 0.00% | -155.04% | 31.36% | 48.16% | 58.78% | 13.45% | 18.99% | 44.65% |
| Research & Development | 2.25M | 1.57M | 530.08K | 330.98K | 1.25M | 1.04M | 974.53K | 1.11M |
| General & Administrative | 3.48M | 2.51M | 2.17M | 777.44K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 962.61K | -199.92K | -86.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.48M | 2.31M | 2.08M | 777.44K | 1.36M | 1.47M | 806.90K | 690.98K |
| Other Expenses | 0.00 | 0.00 | -5.77K | 191.57K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.73M | 3.88M | 2.61M | 1.11M | 2.60M | 2.51M | 1.78M | 1.80M |
| Cost & Expenses | 5.73M | 4.08M | 2.76M | 1.28M | 2.82M | 3.18M | 2.87M | 2.32M |
| Interest Income | 0.00 | 44.88K | 36.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.80K | 90.75K | 208.29K | 287.20K | 182.25K | 230.30K | 179.74K | 50.74K |
| Depreciation & Amortization | 154.23K | 199.92K | 86.44K | 108.76K | 121.53K | 63.64K | 72.64K | 48.86K |
| EBITDA | -5.39M | -3.80M | -3.41M | -649.39K | -2.17M | -2.59M | -1.45M | -1.33M |
| EBITDA Ratio | 0.00% | -4,827.46% | -1,172.50% | -255.23% | -406.99% | -300.06% | -108.65% | -142.21% |
| Operating Income | -5.73M | -4.00M | -2.55M | -949.72K | -2.29M | -2.40M | -1.53M | -1.39M |
| Operating Income Ratio | 0.00% | -5,081.62% | -1,213.66% | -288.24% | -429.78% | -308.23% | -114.08% | -147.41% |
| Total Other Income/Expenses | 104.92K | -97.69K | -1.15M | -95.63K | -182.25K | -486.73K | -179.74K | -49.13K |
| Income Before Tax | -5.63M | -4.09M | -3.70M | -1.05M | -2.47M | -2.89M | -1.71M | -1.43M |
| Income Before Tax Ratio | 0.00% | -5,205.80% | -1,763.64% | -317.26% | -463.97% | -370.70% | -127.50% | -152.64% |
| Income Tax Expense | 0.00 | -1.00 | -4.00 | 1.00 | -2.00 | -4.00 | 4.00 | -2.00 |
| Net Income | -5.63M | -4.09M | -3.70M | -1.05M | -2.47M | -2.89M | -1.71M | -1.43M |
| Net Income Ratio | 0.00% | -5,205.80% | -1,763.64% | -317.26% | -463.97% | -370.70% | -127.50% | -152.64% |
| EPS | -15.03 | -13.78 | -12.46 | -3.57 | -8.46 | -9.88 | -5.84 | -4.90 |
| EPS Diluted | -15.03 | -12.38 | -12.46 | -3.57 | -8.46 | -9.88 | -5.84 | -4.90 |
| Weighted Avg Shares Out | 374.48K | 297.16K | 297.16K | 292.43K | 292.43K | 292.43K | 292.43K | 292.43K |
| Weighted Avg Shares Out (Dil) | 374.48K | 330.65K | 297.16K | 292.43K | 292.43K | 292.43K | 292.43K | 292.43K |
SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition
SeqLL Announces Cash and Stock Dividend Record Date
SeqLL to Conduct 1-for-40 Reverse Stock Split
Why Is SeqLL (SQL) Stock Up 43% Today?
SeqLL stock rockets on heavy volume again, in wake of 2-year development pact with FBI
Why Is SeqLL (SQL) Stock Up 126% Today?
Why Is SeqLL (SQL) Stock Up 256% Today?
SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference
SeqLL Inc. Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering
SeqLL Inc. Announces Closing of Upsized $13 Million Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports